Fighting poor-quality medicines in low- and middle-income countries: the importance of advocacy and pedagogy

Raffaella Ravinetto, Daniel Vandenbergh, Cécile Macé, Corinne Pouget, Brigitte Renchon, Jean Rigal, Benedetta Schiavett, J.M. Caudron

    Research output: Contribution to journalA2: International peer reviewed article (not A1-type)peer-review

    28 Downloads (Pure)


    The globalization of pharmaceutical production has not been accompanied by a strengthening and harmonization of the regulatory systems worldwide. Thus, the global market is characterized today by a situation of multiple standards, and patients in low- and middle-income countries are exposed to the risk of receiving poor-quality medicines. Among those who first raised the alarm on this problem, there were pioneering humanitarian groups, who were in a privileged position to witness the gap in quality of medicines between high-income countries and low- and middle-income countries.

    Despite an increasing awareness of the problem and the launch of some positive initiatives, the divide in pharmaceutical quality between the North and the South remains important, and insufficiently addressed. More advocacy is needed for universal access to quality-assured medicines. It should target all those who are strongly “involved” with medicines: regulators, international organizations, journalists, purchasers, prescribers, program managers, policy makers, public health actors and the patients. Advocacy should be based on evidence from research and monitoring programs, and technical concepts should be translated in lay language through communication tools that address all the stakeholders. The fight to ensure universal access to quality medicines needs the participation of all, and can only be successful if grounded in common understanding.
    Original languageEnglish
    Article number36
    JournalJournal of Pharmaceutical Policy and Practice
    Number of pages4
    Publication statusPublished - 2016


    • B740-pharmacy
    • quality of medicines
    • Developing countries
    • equity in health


    Dive into the research topics of 'Fighting poor-quality medicines in low- and middle-income countries: the importance of advocacy and pedagogy'. Together they form a unique fingerprint.

    Cite this